In the SURMOUNT-1 trial, tirzepatide 15 mg weekly produced mean weight loss of 22.5% at 72 weeks significantly exceeding semaglutide results
In contrast, elevated TMAO levels were associated with hip fractures [15, 16]
Its cardinal objective revolves around inciting the pituitary gland to relinquish growth hormone, a phenomenon proven efficacious in the abatement of visceral fat deposition among individuals grappling with HIV-associated lipodystrophy
For many users, GLP-1 drugs are not a long-term commitment but rather a step along the way in their weight loss or wellness journey
The anti-aging benefits of adequate nutrition become particularly relevant during aggressive weight loss protocols, as nutrient deficiencies can accelerate age-related decline
it may also increase hypoglycaemia risk when combined with sulphonylureas or insulin